Literature DB >> 24052437

Clinical significance of the expression of EGFR signaling pathway-related proteins in esophageal squamous cell carcinoma.

Jian-Cheng Li1, Yun-Hui Zhao, Xiao-Ying Wang, Yan Yang, Ding-Long Pan, Zi-Dan Qiu, Ying Su, Jian-Ji Pan.   

Abstract

Epidermal growth factor receptor (EGFR) signaling is an important pathway that is not only involved in the determination of cellular development, but also has significant roles in tumor development and progression. The study aims to examine the expression of EGFR signaling pathway-related proteins (EGFR, c-Fos, and c-erb-B2) in esophageal squamous cell carcinoma and to investigate their relationships with clinical significance. Sixty esophageal squamous carcinoma specimens obtained by fiber esophagoscope were subjected to two-step immunohistochemistry to test the expression of EGFR, c-Fos, and c-erb-B2. EGFR expression was observed in 73.3% of tumors (44/60); positive EGFR expression was significantly correlated with tumor-node-metastasis (TNM) staging, lymph node metastasis, and distant metastasis (P < 0.05). c-Fos expression was found in 85% (51/60) of tumors, and its expression was significantly related to tumor depth and TNM staging (P < 0.05). c-erb-B2 expression was 75% (45/60) in esophageal squamous cell carcinoma (ESCC) specimens, and positive-erb-B2 expression had a significant association with the depth of tumor invasion (P < 0.05). c-Fos expression was significantly and positively correlated with c-erb-B2 (P < 0.05). Overexpression of EGFR, c-Fos, and c-erb-B2 was associated with tumor progression and development. EGFR and c-Fos expression can predict the tumor stage. c-Fos and c-erb-B2 expression can be used to determine the depth of tumor invasion and can also act as a combined prognostic indicator in ESCC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24052437     DOI: 10.1007/s13277-013-1089-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  20 in total

Review 1.  The epidermal growth factor receptor and its inhibition in cancer therapy.

Authors:  J R Woodburn
Journal:  Pharmacol Ther       Date:  1999 May-Jun       Impact factor: 12.310

Review 2.  Potential therapeutic significance of HER-family in esophageal squamous cell carcinoma.

Authors:  Koji Kono; Kousaku Mimura; Hideki Fujii; Asim Shabbir; Wei-Peng Yong; And Jimmy So
Journal:  Ann Thorac Cardiovasc Surg       Date:  2012-11-17       Impact factor: 1.520

3.  Complete nucleotide sequence of a human c-onc gene: deduced amino acid sequence of the human c-fos protein.

Authors:  F van Straaten; R Müller; T Curran; C Van Beveren; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

Review 4.  Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies.

Authors:  Alessandro Cappetta; Sara Lonardi; Davide Pastorelli; Francesca Bergamo; Giuseppe Lombardi; Vittorina Zagonel
Journal:  Crit Rev Oncol Hematol       Date:  2011-01-20       Impact factor: 6.312

5.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

Review 6.  Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment.

Authors:  Jaume Capdevila; Elena Elez; Teresa Macarulla; Francisco Javier Ramos; Manuel Ruiz-Echarri; Josep Tabernero
Journal:  Cancer Treat Rev       Date:  2009-03-06       Impact factor: 12.111

7.  Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma.

Authors:  Harry H Yoon; Qian Shi; William R Sukov; Mark A Lewis; Christopher A Sattler; Anne E Wiktor; Tsung-Teh Wu; Robert B Diasio; Robert B Jenkins; Frank A Sinicrope
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544

8.  Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma.

Authors:  Neal W Wilkinson; Jennifer D Black; Elena Roukhadze; Deborah Driscoll; Shannon Smiley; Hisakazu Hoshi; Joseph Geradts; Milind Javle; Michael Brattain
Journal:  J Gastrointest Surg       Date:  2004 May-Jun       Impact factor: 3.452

9.  Expression of Egr-1, c-fos and cyclin D1 in esophageal cancer and its precursors: An immunohistochemical and in situ hybridization study.

Authors:  Ming-Yao Wu; Chu-Xiang Zhuang; Huan-Xing Yang; Ying-Rui Liang
Journal:  World J Gastroenterol       Date:  2004-02-15       Impact factor: 5.742

10.  C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma.

Authors:  S Mahner; C Baasch; J Schwarz; S Hein; L Wölber; F Jänicke; K Milde-Langosch
Journal:  Br J Cancer       Date:  2008-10-21       Impact factor: 7.640

View more
  11 in total

1.  Assessment of epidermal growth factor receptor mutation/copy number and K-ras mutation in esophageal cancer.

Authors:  Kang Guo; Wu-Ping Wang; Tao Jiang; Ju-Zheng Wang; Zhao Chen; Yong Li; Yong-An Zhou; Xiao-Fei Li; Qiang Lu; Lan-Jun Zhang
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

2.  C-Met as a Molecular Marker for Esophageal Squamous Cell Carcinoma and Its Association with Clinical Outcome.

Authors:  Ya-Ping Xu; Gang Lin; Xiao-Jiang Sun; Mao-Hui Yan; Gu Zhang; Jin-Lin Hu; Wen-Yong Sun; Jin-Ming Yu
Journal:  J Cancer       Date:  2016-03-18       Impact factor: 4.207

Review 3.  Squamous Cell Cancers: A Unified Perspective on Biology and Genetics.

Authors:  G Paolo Dotto; Anil K Rustgi
Journal:  Cancer Cell       Date:  2016-05-09       Impact factor: 31.743

4.  Pan-cancer transcriptome analysis reveals a gene expression signature for the identification of tumor tissue origin.

Authors:  Qinghua Xu; Jinying Chen; Shujuan Ni; Cong Tan; Midie Xu; Lei Dong; Lin Yuan; Qifeng Wang; Xiang Du
Journal:  Mod Pathol       Date:  2016-03-18       Impact factor: 7.842

5.  Expression of epidermal growth factor receptor in oral and esophageal squamous-cell carcinoma.

Authors:  Fatemeh Shahsavari; Rosa Miri; Maedeh Ghorbanpour
Journal:  Dent Res J (Isfahan)       Date:  2020-03-17

6.  Phase I dose-escalation trial of Sym004, an anti-EGFR antibody mixture, in Japanese patients with advanced solid tumors.

Authors:  Takashi Kojima; Kentaro Yamazaki; Ken Kato; Kei Muro; Hiroki Hara; Keisho Chin; Thomas Goddemeier; Stefan Kuffel; Morihiro Watanabe; Toshihiko Doi
Journal:  Cancer Sci       Date:  2018-09-25       Impact factor: 6.716

7.  A five-gene signature to predict the overall survival time of patients with esophageal squamous cell carcinoma.

Authors:  Wenwu He; Qunlun Yan; Liangmin Fu; Yongtao Han
Journal:  Oncol Lett       Date:  2019-06-07       Impact factor: 2.967

8.  Coexpression of periostin and EGFR in patients with esophageal squamous cell carcinoma and their prognostic significance.

Authors:  Wei Jia; Wei Wang; Chu-Shu Ji; Jun-Yang Niu; Ya-Jing Lv; Hang-Cheng Zhou; Bing Hu
Journal:  Onco Targets Ther       Date:  2016-08-18       Impact factor: 4.147

9.  MiR-193a-5p/ERBB2 act as concurrent chemoradiation therapy response indicator of esophageal squamous cell carcinoma.

Authors:  Cheng-Han Lin; Chen-Hsun Tsai; Ching-Tung Yeh; Jui-Lin Liang; Wan-Chun Hung; Forn-Chia Lin; Wei-Lun Chang; Hao-Yi Li; Yun-Chin Yao; Tai-I Hsu; Yu-Cheng Lee; Yi-Ching Wang; Bor-Shyang Sheu; Wu-Wei Lai; Marcus J Calkins; Michael Hsiao; Pei-Jung Lu
Journal:  Oncotarget       Date:  2016-06-28

10.  Overexpression of Epidermal Growth Factor Receptor (EGFR) and HER-2 in Bladder Carcinoma and Its Association with Patients' Clinical Features.

Authors:  Wei Li; Youquan Wang; Shubo Tan; Qishuo Rao; Tian Zhu; Guo Huang; Zhuo Li; Guowen Liu
Journal:  Med Sci Monit       Date:  2018-10-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.